These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 2501899

  • 1. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
    Wojta J, Binder BR, Huber K, Hoover RL.
    Thromb Haemost; 1989 Apr 25; 61(2):289-93. PubMed ID: 2501899
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
    Declerck PJ, Van Keer L, Verstreken M, Collen D.
    Thromb Haemost; 1992 Jan 23; 67(1):95-100. PubMed ID: 1377417
    [Abstract] [Full Text] [Related]

  • 4. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 5. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
    Darras V, Thienpont M, Stump DC, Collen D.
    Thromb Haemost; 1986 Dec 15; 56(3):411-4. PubMed ID: 3105111
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
    Wojta J, Turcu L, Wagner OF, Korninger C, Binder BR.
    J Lab Clin Med; 1987 Jun 15; 109(6):665-71. PubMed ID: 3108431
    [Abstract] [Full Text] [Related]

  • 8. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 9. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM, Dosne AM, Kher A, Samama M.
    Thromb Haemost; 1989 Nov 24; 62(3):923-6. PubMed ID: 2556812
    [Abstract] [Full Text] [Related]

  • 10. Fibrin-specific thrombolytic agents.
    Collen D.
    Schweiz Med Wochenschr; 1987 Nov 14; 117(46):1791-8. PubMed ID: 3122317
    [Abstract] [Full Text] [Related]

  • 11. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov 14; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

  • 12. A sensitive bioimmunoassay for thrombin-cleaved two-chain urokinase-type plasminogen activator in human body fluids.
    Braat EA, Nauland U, Dooijewaard G, Rijken DC.
    Thromb Haemost; 1996 Jun 14; 75(6):908-14. PubMed ID: 8822585
    [Abstract] [Full Text] [Related]

  • 13. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D.
    Thromb Haemost; 1988 Oct 31; 60(2):247-50. PubMed ID: 3146141
    [Abstract] [Full Text] [Related]

  • 14. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M, Cavallo LG, Agnelli G, Mele A, Bürgi R, Heim J, Semeraro N.
    Thromb Haemost; 1993 May 03; 69(5):466-72. PubMed ID: 8391727
    [Abstract] [Full Text] [Related]

  • 15. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D.
    Prog Hemost Thromb; 1986 May 03; 8():1-18. PubMed ID: 3104986
    [No Abstract] [Full Text] [Related]

  • 16. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F.
    Arzneimittelforschung; 1988 Mar 03; 38(3A):474-8. PubMed ID: 3134901
    [Abstract] [Full Text] [Related]

  • 17. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET, Mack DL, Sobel BE.
    Thromb Haemost; 1989 Nov 24; 62(3):909-16. PubMed ID: 2512679
    [Abstract] [Full Text] [Related]

  • 18. Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immunoadsorbent-amidolytic assay (IAA).
    Corti A, Nolli ML, Cassani G.
    Thromb Haemost; 1986 Dec 15; 56(3):407-10. PubMed ID: 3105110
    [Abstract] [Full Text] [Related]

  • 19. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass.
    Spannagl M, Dooijewaard G, Dietrich W, Kluft C.
    Thromb Haemost; 1995 May 15; 73(5):825-8. PubMed ID: 7482410
    [Abstract] [Full Text] [Related]

  • 20. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.